News for Annovis Bio, Inc. (ANVS)

On May 15, 2025, Canaccord Genuity, led by analyst Sumant Kulkarni, updated its position on Annovis Bio (ANVS). The firm's analyst maintained a 'Buy' rating for

Cash Position: Cash and cash equivalents increased to $22.2 million as of March 31, 2025, from $10.6 million a year earlier, reflecting a strong liquidity posi

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis" or the ”œCompany”), a late-stage clinical drug platform company pioneer

Annovis Bio (ANVS) has successfully initiated its pivotal Phase 3 trial for early Alzheimer's disease. The company reported a strong cas

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developin

Several biotech firms are witnessing a remarkable surge in interest, driven by increased search activity, according to InvestingChannel data. Annovis Bio (ANVS)

**media[578946]**

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the ”œCompany”), a late-stage clinical drug platform company p

**media[573340]**

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative

MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS)  (“Annovis” or the “Company”), a clinical-stage drug platform company deve…

**media[534970]**

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company p…

**media[532257]**

Late-stage clinical drug platform company Annovis Bio, Inc. (ANVS), Monday announced the pricing of 5.25 million common stock and warrants to purchase an equal number of shares at a combined price of $4 per share, amounting to a total of $21 million.

**media[530590]**

**media[529417]**

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company …